APA (7th ed.) Citation

Li J, Jia Y, Shao C, Li Y, & Song J. (2023). Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Dove Medical Press.

Chicago Style (17th ed.) Citation

Li J, Jia Y, Shao C, Li Y, and Song J. Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Dove Medical Press, 2023.

MLA (9th ed.) Citation

Li J, et al. Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Dove Medical Press, 2023.